<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076512/results/search/country/results.xml">
  <result pre="the oral bioavailability of the drug studied in vivo in" exact="New Zealand" post="rabbits, a reduced frequency of dosing being needed in"/>
  <result pre="November 2019) 7.SzucsT.D.BergerK.FismanD.N.HarbarthS.The estimated economic burden of genital herpes in" exact="the United States." post="An analysis using two costing approachesBMC Infect. Dis.20011510.1186/1471-2334-1-511472635 8.GonzaloT.García"/>
  <result pre="2019) 7.SzucsT.D.BergerK.FismanD.N.HarbarthS.The estimated economic burden of genital herpes in the" exact="United States." post="An analysis using two costing approachesBMC Infect. Dis.20011510.1186/1471-2334-1-511472635 8.GonzaloT.García"/>
  <result pre="Route of Administration REF Epaxal® Crucell (former Berna Biotech Ltd.);1994" exact="Switzerland" post="Virosomes (around 150 nm spherical liposomal vesicles)—intrinsic adjuvant properties;"/>
  <result pre="Intramuscular vaccine [186,187] Inflexal® V Crucell (former Berna Biotech Ltd.);1997" exact="Switzerland" post="Virosomes (around 150 nm spherical liposomal vesicles)—biodegradable and biocompatible"/>
  <result pre="stability; HBV, HCV Subcutaneous [190,191] Influvac® Plus BGP Pharma ULC,2005," exact="Canada" post="Virosome vaccine Influenza Intramuscularvaccine [192] VivaGel® BV Starpharma, Australia;Mundipharma,"/>
 </snippets>
</snippetsTree>
